Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17845289 | 0.85 | ALDH1A1 (0.45) | HSD11B1ALDH1A1HSD17B10ALOX15MAPT | |
| SCHEMBL13589485 | 0.82 | ENPP2 (0.48) | HSD11B1SMN1; SMN2ALDH1A1RAB9AHSD17B10 | |
| SCHEMBL483015 | 0.82 | HSD11B1 (0.48) | HSD11B1SMN1; SMN2ALDH1A1RAB9AHSD17B10 | |
| SCHEMBL14341655 | 0.81 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1RAB9AHSD17B10ALOX15 | |
| Hydrochloric Acid SCHEMBL27809979 | 0.81 | HSD11B1 (0.47) | HSD11B1SMN1; SMN2ALDH1A1RAB9AHSD17B10 | |
| SCHEMBL8336238 | 0.78 | ALOX15 (0.53) | SMN1; SMN2ALDH1A1RAB9AHSD17B10ALOX15 | |
| SCHEMBL14412995 | 0.78 | ALOX15 (0.46) | HSD11B1SMN1; SMN2ALDH1A1RAB9AHSD17B10 | |
| SCHEMBL13588738 | 0.78 | SMN1; SMN2 (0.45) | HSD11B1SMN1; SMN2ALDH1A1RAB9AHSD17B10 | |
| SCHEMBL295564 | 0.77 | ALDH1A1 (0.61) | ALDH1A1RAB9AHSD17B10ALOX15MAPT | |
| SCHEMBL17863663 | 0.76 | LMNA (0.54) | SMN1; SMN2ALDH1A1POLBLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3645533-B1 | TDO2 AND IDO1 INHIBITORS | GENENTECH INC (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023202583-A1 | FXR REGULATOR AND USE THEREOF | 北京大学 | 2023-10-26 | — | — | WO | disclosed |
| CN-116903559-A | FXR modulators and uses thereof | 北京大学 | 2023-10-20 | — | — | CN | disclosed |
| US-11603373-B2 | TDO2 and IDO1 inhibitors | GENENTECH, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-3645533-A1 | TDO2 AND IDO1 INHIBITORS | Genentech, Inc. (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20200123163-A1 | TDO2 and IDO1 Inhibitors | GENENTECH, INC. | 2020-04-23 | — | — | US | disclosed |
| WO-2019005559-A1 | TDO2 AND IDO1 INHIBITORS | GENENTECH, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-5767283-A | CHEMICAL INTERMEDIATE FOR 7-N-ORGANOSULFONYL-1H-INDOLE DERIVATIVE ANTITUMOR AGENTS; NONTOXIC | EISAI CO., LTD. (JP) | 1998-06-16 | — | — | US | disclosed |
| US-5721246-A | ANTITUMOR AGENTS; LOW TOXICITY | EISAI CO., LTD. (JP) | 1998-02-24 | — | — | US | disclosed |
| US-5663414-A | INHIBITS PHOSPHOLIPASE ACTIVITY; ANTIISCHEMIC AGENTS; TREATMENT OF CARDIAC INFRACTION | EISAI CO., LTD. (JP) | 1997-09-02 | — | — | US | disclosed |
| EP-0468054-B1 | BENZENESULFONAMIDE DERIVATIVE | EISAI CO LTD (JP) | 1997-05-28 | — | — | EP | disclosed |
| US-5530118-A | PHOSPHOLIPASE INHIBITOR | EISAI CO., LTD. (JP) | 1996-06-25 | — | — | US | disclosed |
| EP-0687249-A1 | BALANOIDS | ELI LILLY AND COMPANY (US) | 1995-12-20 | — | — | EP | disclosed |
| EP-0673937-A1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994020062-A2 | BALANOIDS AS PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1994-09-15 | — | — | WO | disclosed |
| US-5281626-A | Antiischemic agents, cardiovascular disorders or enzyme inhibitors | EISAI CO., LTD. (JP) | 1994-01-25 | — | — | US | disclosed |
| EP-0468054-A1 | BENZENESULFONAMIDE DERIVATIVE | Eisai Co., Ltd. (JP) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603373-B2 | TDO2 and IDO1 inhibitors | IDO1, TDO2, IDO2 | HSD11B1 785/4885SMN1; SMN2 4143/4885ALDH1A1 855/4885 |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | ITGB5, ITGB1, ITGB2 | HSD11B1 1779/4885SMN1; SMN2 2639/4885ALDH1A1 1256/4885 |
| US-20200123163-A1 | TDO2 and IDO1 Inhibitors | IDO1, TDO2, IDO2 | HSD11B1 785/4885SMN1; SMN2 4143/4885ALDH1A1 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.